Zacks Small Cap Analysis – XFOR: XOLREMDI Accepted by FDA… – Nexus Vista

By David Bautz, PhD NASDAQ:XFOR READ THE FULL XFOR RESEARCH REPORT Enterprise Replace XOLREMDI Accepted by the FDA On April 29, 2024, X4 Prescription drugs, Inc. (NASDAQ:XFOR) introduced that the U.S. Meals and Drug Administration (FDA) has permitted XOLREMDI (mavorixafor) to be used in sufferers 12 years of age and older with WHIM syndrome (warts, … Read more